APO Research
Talk to an analyst

APO RESEARCH · REPORT

Postmenopausal Vaginal Atrophy Drugs

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Postmenopausal Vaginal Atrophy Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

22 December 2025183 pages

Choose your research edition.

Industry ResearchPostmenopausal Vaginal Atrophy Drugs Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal Postmenopausal Vaginal Atrophy Drugs Industry Growth and Trends Forecast to 203293 pages · $3,450 USDMarket StructureGlobal Postmenopausal Vaginal Atrophy Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032183 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Postmenopausal Vaginal Atrophy Drugs Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Postmenopausal Vaginal Atrophy Drugs Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Postmenopausal Vaginal Atrophy Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Postmenopausal Vaginal Atrophy Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Postmenopausal Vaginal Atrophy Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Postmenopausal Vaginal Atrophy Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Postmenopausal Vaginal Atrophy Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Postmenopausal Vaginal Atrophy Drugs include Teva Pharmaceutical Industries, Novo Nordisk, Pfizer, Millicent Pharma, Endoceutics, Duchesnay USA and Aspen Pharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Postmenopausal Vaginal Atrophy Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Postmenopausal Vaginal Atrophy Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Postmenopausal Vaginal Atrophy Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Postmenopausal Vaginal Atrophy Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Postmenopausal Vaginal Atrophy Drugs Segment by Company

Teva Pharmaceutical Industries

Novo Nordisk

Pfizer

Millicent Pharma

Endoceutics

Duchesnay USA

Aspen Pharma

Postmenopausal Vaginal Atrophy Drugs Segment by Type

Tablets

Suppositories

Creams

Rings

Postmenopausal Vaginal Atrophy Drugs Segment by Application

Offline Stores

Online Stores

Postmenopausal Vaginal Atrophy Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Postmenopausal Vaginal Atrophy Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Postmenopausal Vaginal Atrophy Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Postmenopausal Vaginal Atrophy Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Postmenopausal Vaginal Atrophy Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Postmenopausal Vaginal Atrophy Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Postmenopausal Vaginal Atrophy Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Postmenopausal Vaginal Atrophy Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Postmenopausal Vaginal Atrophy Drugs Industry Trends Table 2. Postmenopausal Vaginal Atrophy Drugs Industry Drivers Table 3. Postmenopausal Vaginal Atrophy Drugs Industry Opportunities and Challenges Table 4. Postmenopausal Vaginal Atrophy Drugs Industry Restraints Table 5. Global Postmenopausal Vaginal Atrophy Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Postmenopausal Vaginal Atrophy Drugs Sales by Manufacturers (k units) & (2021-2026) Table 8. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Manufacturers Table 9. Global Postmenopausal Vaginal Atrophy Drugs Average Sales Price (US$/unit) of Manufacturers (2021-2026) Table 10. Global Postmenopausal Vaginal Atrophy Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Postmenopausal Vaginal Atrophy Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Postmenopausal Vaginal Atrophy Drugs Manufacturers, Product Type & Application Table 13. Global Postmenopausal Vaginal Atrophy Drugs Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Postmenopausal Vaginal Atrophy Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Tablets Table 17. Major Manufacturers of Suppositories Table 18. Major Manufacturers of Creams Table 19. Major Manufacturers of Rings Table 20. Global Postmenopausal Vaginal Atrophy Drugs Sales by Type 2021 VS 2025 VS 2032 (k units) Table 21. Global Postmenopausal Vaginal Atrophy Drugs Sales by Type (2021-2026) & (k units) Table 22. Global Postmenopausal Vaginal Atrophy Drugs Sales by Type (2027-2032) & (k units) Table 23. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Type (2021-2026) Table 24. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Type (2027-2032) Table 25. Global Postmenopausal Vaginal Atrophy Drugs Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 26. Global Postmenopausal Vaginal Atrophy Drugs Revenue by Type (2021-2026) & (k units) Table 27. Global Postmenopausal Vaginal Atrophy Drugs Revenue by Type (2027-2032) & (k units) Table 28. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Type (2021-2026) Table 29. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Type (2027-2032) Table 30. Major Manufacturers of Offline Stores Table 31. Major Manufacturers of Online Stores Table 32. Global Postmenopausal Vaginal Atrophy Drugs Sales by Application 2021 VS 2025 VS 2032 (k units) Table 33. Global Postmenopausal Vaginal Atrophy Drugs Sales by Application (2021-2026) & (k units) Table 34. Global Postmenopausal Vaginal Atrophy Drugs Sales by Application (2027-2032) & (k units) Table 35. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Application (2021-2026) Table 36. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Application (2027-2032) Table 37. Global Postmenopausal Vaginal Atrophy Drugs Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 38. Global Postmenopausal Vaginal Atrophy Drugs Revenue by Application (2021-2026) & (k units) Table 39. Global Postmenopausal Vaginal Atrophy Drugs Revenue by Application (2027-2032) & (k units) Table 40. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Application (2021-2026) Table 41. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Application (2027-2032) Table 42. Global Postmenopausal Vaginal Atrophy Drugs Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 43. Global Postmenopausal Vaginal Atrophy Drugs Sales by Region (2021-2026) & (k units) Table 44. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Region (2021-2026) Table 45. Global Postmenopausal Vaginal Atrophy Drugs Sales Forecasted by Region (2027-2032) & (k units) Table 46. Global Postmenopausal Vaginal Atrophy Drugs Sales Forecasted Market Share by Region (2027-2032) Table 47. North America Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 48. North America Postmenopausal Vaginal Atrophy Drugs Sales by Country (2021-2026) & (k units) Table 49. North America Postmenopausal Vaginal Atrophy Drugs Sales by Country (2027-2032) & (k units) Table 50. Europe Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 51. Europe Postmenopausal Vaginal Atrophy Drugs Sales by Country (2021-2026) & (k units) Table 52. Europe Postmenopausal Vaginal Atrophy Drugs Sales by Country (2027-2032) & (k units) Table 53. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 54. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Sales by Country (2021-2026) & (k units) Table 55. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Sales by Country (2027-2032) & (k units) Table 56. South America, Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 57. South America, Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales by Country (2021-2026) & (k units) Table 58. South America, Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales by Country (2027-2032) & (k units) Table 59. Global Postmenopausal Vaginal Atrophy Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Postmenopausal Vaginal Atrophy Drugs Revenue by Region (2021-2026) & (US$ Million) Table 61. Global Postmenopausal Vaginal Atrophy Drugs Revenue by Region (2027-2032) & (US$ Million) Table 62. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Region (2021-2026) Table 63. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Region (2027-2032) Table 64. Teva Pharmaceutical Industries Company Information Table 65. Teva Pharmaceutical Industries Business Overview Table 66. Teva Pharmaceutical Industries Postmenopausal Vaginal Atrophy Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Teva Pharmaceutical Industries Postmenopausal Vaginal Atrophy Drugs Product Portfolio Table 68. Teva Pharmaceutical Industries Recent Development Table 69. Novo Nordisk Company Information Table 70. Novo Nordisk Business Overview Table 71. Novo Nordisk Postmenopausal Vaginal Atrophy Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Novo Nordisk Postmenopausal Vaginal Atrophy Drugs Product Portfolio Table 73. Novo Nordisk Recent Development Table 74. Pfizer Company Information Table 75. Pfizer Business Overview Table 76. Pfizer Postmenopausal Vaginal Atrophy Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Pfizer Postmenopausal Vaginal Atrophy Drugs Product Portfolio Table 78. Pfizer Recent Development Table 79. Millicent Pharma Company Information Table 80. Millicent Pharma Business Overview Table 81. Millicent Pharma Postmenopausal Vaginal Atrophy Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Millicent Pharma Postmenopausal Vaginal Atrophy Drugs Product Portfolio Table 83. Millicent Pharma Recent Development Table 84. Endoceutics Company Information Table 85. Endoceutics Business Overview Table 86. Endoceutics Postmenopausal Vaginal Atrophy Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Endoceutics Postmenopausal Vaginal Atrophy Drugs Product Portfolio Table 88. Endoceutics Recent Development Table 89. Duchesnay USA Company Information Table 90. Duchesnay USA Business Overview Table 91. Duchesnay USA Postmenopausal Vaginal Atrophy Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. Duchesnay USA Postmenopausal Vaginal Atrophy Drugs Product Portfolio Table 93. Duchesnay USA Recent Development Table 94. Aspen Pharma Company Information Table 95. Aspen Pharma Business Overview Table 96. Aspen Pharma Postmenopausal Vaginal Atrophy Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 97. Aspen Pharma Postmenopausal Vaginal Atrophy Drugs Product Portfolio Table 98. Aspen Pharma Recent Development Table 99. Key Raw Materials Table 100. Raw Materials Key Suppliers Table 101. Postmenopausal Vaginal Atrophy Drugs Distributors List Table 102. Postmenopausal Vaginal Atrophy Drugs Customers List Table 103. Research Programs/Design for This Report Table 104. Authors List of This Report Table 105. Secondary Sources Table 106. Primary Sources List of Figures Figure 1. Postmenopausal Vaginal Atrophy Drugs Product Image Figure 2. Global Postmenopausal Vaginal Atrophy Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Postmenopausal Vaginal Atrophy Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Postmenopausal Vaginal Atrophy Drugs Sales (2021-2032) & (k units) Figure 5. Global Postmenopausal Vaginal Atrophy Drugs Average Price (US$/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Postmenopausal Vaginal Atrophy Drugs Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Tablets Image Figure 9. Suppositories Image Figure 10. Creams Image Figure 11. Rings Image Figure 12. Global Postmenopausal Vaginal Atrophy Drugs Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 13. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 14. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Type (2021-2032) Figure 15. Global Postmenopausal Vaginal Atrophy Drugs Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 16. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Type (2021-2032) Figure 18. Offline Stores Image Figure 19. Online Stores Image Figure 20. Global Postmenopausal Vaginal Atrophy Drugs Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 21. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 22. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Application (2021-2032) Figure 23. Global Postmenopausal Vaginal Atrophy Drugs Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 24. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 25. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Application (2021-2032) Figure 26. North America Postmenopausal Vaginal Atrophy Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 27. North America Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Country (2021-2032) Figure 28. U.S. Postmenopausal Vaginal Atrophy Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 29. Canada Postmenopausal Vaginal Atrophy Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 30. Mexico Postmenopausal Vaginal Atrophy Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 31. Europe Postmenopausal Vaginal Atrophy Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 32. Europe Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Country (2021-2032) Figure 33. Germany Postmenopausal Vaginal Atrophy Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 34. France Postmenopausal Vaginal Atrophy Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 35. U.K. Postmenopausal Vaginal Atrophy Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 36. Italy Postmenopausal Vaginal Atrophy Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 37. Netherlands Postmenopausal Vaginal Atrophy Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 38. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 39. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Country (2021-2032) Figure 40. China Postmenopausal Vaginal Atrophy Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 41. Japan Postmenopausal Vaginal Atrophy Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 42. South Korea Postmenopausal Vaginal Atrophy Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 43. Southeast Asia Postmenopausal Vaginal Atrophy Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 44. India Postmenopausal Vaginal Atrophy Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 45. Australia Postmenopausal Vaginal Atrophy Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 46. South America, Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 47. South America, Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Country (2021-2032) Figure 48. Brazil Postmenopausal Vaginal Atrophy Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 49. South Africa Postmenopausal Vaginal Atrophy Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 50. Saudi Arabia Postmenopausal Vaginal Atrophy Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 51. Turkey Postmenopausal Vaginal Atrophy Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 52. Argentina Postmenopausal Vaginal Atrophy Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 53. UAE Postmenopausal Vaginal Atrophy Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 54. Egypt Postmenopausal Vaginal Atrophy Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 55. Chile Postmenopausal Vaginal Atrophy Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 56. Global Postmenopausal Vaginal Atrophy Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 57. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 58. North America Postmenopausal Vaginal Atrophy Drugs Revenue (2021-2032) & (US$ Million) Figure 59. North America Postmenopausal Vaginal Atrophy Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Europe Postmenopausal Vaginal Atrophy Drugs Revenue (2021-2032) & (US$ Million) Figure 61. Europe Postmenopausal Vaginal Atrophy Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Revenue (2021-2032) & (US$ Million) Figure 63. Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. South America, Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Revenue (2021-2032) & (US$ Million) Figure 65. South America, Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Postmenopausal Vaginal Atrophy Drugs Value Chain Figure 67. Manufacturing Cost Structure Figure 68. Postmenopausal Vaginal Atrophy Drugs Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Tablets
  • Suppositories
  • Creams
  • Rings
Applications
  • Offline Stores
  • Online Stores
Companies covered
  • Teva Pharmaceutical Industries
  • Novo Nordisk
  • Pfizer
  • Millicent Pharma
  • Endoceutics
  • Duchesnay USA
  • Aspen Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Postmenopausal Vaginal Atrophy Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Postmenopausal Vaginal Atrophy Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Postmenopausal Vaginal Atrophy Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Postmenopausal Vaginal Atrophy Drugs Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Postmenopausal Vaginal Atrophy Drugs Market Dynamics
  1. 2.1 Postmenopausal Vaginal Atrophy Drugs Industry Trends
  2. 2.2 Postmenopausal Vaginal Atrophy Drugs Industry Drivers
  3. 2.3 Postmenopausal Vaginal Atrophy Drugs Industry Opportunities and Challenges
  4. 2.4 Postmenopausal Vaginal Atrophy Drugs Industry Restraints
3 Postmenopausal Vaginal Atrophy Drugs Market by Manufacturers
  1. 3.1 Global Postmenopausal Vaginal Atrophy Drugs Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Postmenopausal Vaginal Atrophy Drugs Sales by Manufacturers (2021-2026)
  3. 3.3 Global Postmenopausal Vaginal Atrophy Drugs Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Postmenopausal Vaginal Atrophy Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Postmenopausal Vaginal Atrophy Drugs Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Postmenopausal Vaginal Atrophy Drugs Manufacturers, Product Type & Application
  7. 3.7 Global Postmenopausal Vaginal Atrophy Drugs Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Postmenopausal Vaginal Atrophy Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Postmenopausal Vaginal Atrophy Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Postmenopausal Vaginal Atrophy Drugs Tier 1, Tier 2, and Tier 3
4 Postmenopausal Vaginal Atrophy Drugs Market by Type
  1. 4.1 Postmenopausal Vaginal Atrophy Drugs Type Introduction
  2. 4.1.1 Tablets
  3. 4.1.2 Suppositories
  4. 4.1.3 Creams
  5. 4.1.4 Rings
  6. 4.2 Global Postmenopausal Vaginal Atrophy Drugs Sales by Type
  7. 4.2.1 Global Postmenopausal Vaginal Atrophy Drugs Sales by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Postmenopausal Vaginal Atrophy Drugs Sales by Type (2021-2032)
  9. 4.2.3 Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Type (2021-2032)
  10. 4.3 Global Postmenopausal Vaginal Atrophy Drugs Revenue by Type
  11. 4.3.1 Global Postmenopausal Vaginal Atrophy Drugs Revenue by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue by Type (2021-2032)
  13. 4.3.3 Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Type (2021-2032)
5 Postmenopausal Vaginal Atrophy Drugs Market by Application
  1. 5.1 Postmenopausal Vaginal Atrophy Drugs Application Introduction
  2. 5.1.1 Offline Stores
  3. 5.1.2 Online Stores
  4. 5.2 Global Postmenopausal Vaginal Atrophy Drugs Sales by Application
  5. 5.2.1 Global Postmenopausal Vaginal Atrophy Drugs Sales by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Postmenopausal Vaginal Atrophy Drugs Sales by Application (2021-2032)
  7. 5.2.3 Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Application (2021-2032)
  8. 5.3 Global Postmenopausal Vaginal Atrophy Drugs Revenue by Application
  9. 5.3.1 Global Postmenopausal Vaginal Atrophy Drugs Revenue by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue by Application (2021-2032)
  11. 5.3.3 Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Application (2021-2032)
6 Global Postmenopausal Vaginal Atrophy Drugs Sales by Region
  1. 6.1 Global Postmenopausal Vaginal Atrophy Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Postmenopausal Vaginal Atrophy Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Postmenopausal Vaginal Atrophy Drugs Sales by Region (2021-2026)
  4. 6.2.2 Global Postmenopausal Vaginal Atrophy Drugs Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Postmenopausal Vaginal Atrophy Drugs Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Postmenopausal Vaginal Atrophy Drugs Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Postmenopausal Vaginal Atrophy Drugs Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Postmenopausal Vaginal Atrophy Drugs Revenue by Region
  1. 7.1 Global Postmenopausal Vaginal Atrophy Drugs Revenue by Region
  2. 7.1.1 Global Postmenopausal Vaginal Atrophy Drugs Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue by Region (2021-2026)
  4. 7.1.3 Global Postmenopausal Vaginal Atrophy Drugs Revenue by Region (2027-2032)
  5. 7.1.4 Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Postmenopausal Vaginal Atrophy Drugs Revenue (2021-2032)
  8. 7.2.2 North America Postmenopausal Vaginal Atrophy Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Postmenopausal Vaginal Atrophy Drugs Revenue (2021-2032)
  11. 7.3.2 Europe Postmenopausal Vaginal Atrophy Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Teva Pharmaceutical Industries
  2. 8.1.1 Teva Pharmaceutical Industries Company Information
  3. 8.1.2 Teva Pharmaceutical Industries Business Overview
  4. 8.1.3 Teva Pharmaceutical Industries Postmenopausal Vaginal Atrophy Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Teva Pharmaceutical Industries Postmenopausal Vaginal Atrophy Drugs Product Portfolio
  6. 8.1.5 Teva Pharmaceutical Industries Recent Developments
  7. 8.2 Novo Nordisk
  8. 8.2.1 Novo Nordisk Company Information
  9. 8.2.2 Novo Nordisk Business Overview
  10. 8.2.3 Novo Nordisk Postmenopausal Vaginal Atrophy Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Novo Nordisk Postmenopausal Vaginal Atrophy Drugs Product Portfolio
  12. 8.2.5 Novo Nordisk Recent Developments
  13. 8.3 Pfizer
  14. 8.3.1 Pfizer Company Information
  15. 8.3.2 Pfizer Business Overview
  16. 8.3.3 Pfizer Postmenopausal Vaginal Atrophy Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Pfizer Postmenopausal Vaginal Atrophy Drugs Product Portfolio
  18. 8.3.5 Pfizer Recent Developments
  19. 8.4 Millicent Pharma
  20. 8.4.1 Millicent Pharma Company Information
  21. 8.4.2 Millicent Pharma Business Overview
  22. 8.4.3 Millicent Pharma Postmenopausal Vaginal Atrophy Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Millicent Pharma Postmenopausal Vaginal Atrophy Drugs Product Portfolio
  24. 8.4.5 Millicent Pharma Recent Developments
  25. 8.5 Endoceutics
  26. 8.5.1 Endoceutics Company Information
  27. 8.5.2 Endoceutics Business Overview
  28. 8.5.3 Endoceutics Postmenopausal Vaginal Atrophy Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Endoceutics Postmenopausal Vaginal Atrophy Drugs Product Portfolio
  30. 8.5.5 Endoceutics Recent Developments
  31. 8.6 Duchesnay USA
  32. 8.6.1 Duchesnay USA Company Information
  33. 8.6.2 Duchesnay USA Business Overview
  34. 8.6.3 Duchesnay USA Postmenopausal Vaginal Atrophy Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Duchesnay USA Postmenopausal Vaginal Atrophy Drugs Product Portfolio
  36. 8.6.5 Duchesnay USA Recent Developments
  37. 8.7 Aspen Pharma
  38. 8.7.1 Aspen Pharma Company Information
  39. 8.7.2 Aspen Pharma Business Overview
  40. 8.7.3 Aspen Pharma Postmenopausal Vaginal Atrophy Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Aspen Pharma Postmenopausal Vaginal Atrophy Drugs Product Portfolio
  42. 8.7.5 Aspen Pharma Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Postmenopausal Vaginal Atrophy Drugs Value Chain Analysis
  2. 9.1.1 Postmenopausal Vaginal Atrophy Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Postmenopausal Vaginal Atrophy Drugs Production Mode & Process
  6. 9.2 Postmenopausal Vaginal Atrophy Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Postmenopausal Vaginal Atrophy Drugs Distributors
  9. 9.2.3 Postmenopausal Vaginal Atrophy Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst